Xenia Chiu

Xenia Chiu focuses her practice on venture capital and growth equity transactions, private equity transactions, mergers and acquisitions, joint ventures and other corporate matters. She advises startups and emerging growth companies at all stages of their corporate lifecycles, including initial company formation, day-to-day corporate governance matters, early and late stage venture financings and exit opportunities such as mergers and acquisitions. She also represents venture capital and private equity investors in financing transactions in the U.S. and Asia.

Prior to joining Cooley and relocating to Singapore, Xenia was an associate at the Chicago office of an international law firm where she represented strategic and financial buyers and sellers in public and private acquisitions as well as counseled public companies on corporate governance matters.

Xenia Chu is a native English speaker, fluent in reading and writing Chinese, and also fluent in speaking Cantonese.

Representative Matters:

• Allozymes, a fast-growing biotechnology company that applies its proprietary ultra-high-throughput platform technology to rapidly develop novel enzymes and unlock the bioeconomy across sectors, in its $15 million Series A financing. 
• Bridge to Life, an organ preservation and perfusion technologies supplier, in its sale of certain assets, including its EVOSS heart and lung and LifeCradle heart perfusion assets to TransMedics.
• Kredivo Holdings (formerly known as FinAccel), a top Southeast Asian digital financial services platform, in its $270 million Series D fundraising round.
• Holmusk, in its $45 million Series B financing.
• Groww, an online investment platform that allows users to invest in mutual funds and stock, in its $251 million Series E round, which brings the company’s valuation to $3 billion.